CoChat
Sign Up
Cited by 858

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Inflammatory Cytokine Alterations in Schizophrenia: A Systematic Quantitative Review

Potvin, Stéphane, Stip, Emmanuel, Sepehry, Amir A., Gendron, Alain, Bah, Ramatoulaye, Kouassi, Edouard·2008·Biological Psychiatry
DOI 10.1016/j.biopsych.2007.09.024
Open this paper in CoChat — free account

Abstract

Background Cytokines play an important role in infection and inflammation and are crucial mediators of the cross-talk between the brain and the immune system. Schizophrenia would be associated with an imbalance in inflammatory cytokines, leading to a decrease in Th1 and an increase in Th2 cytokine secretion. However, data published so far have been inconsistent. The primary objective of the present meta-analysis was to verify whether the cytokine imbalance hypothesis of schizophrenia is substantiated by evidence. Methods Cross-sectional studies were included if they assessed in vivo plasma or serum cytokine concentrations and/or in vitro secretion of cytokines by peripheral blood leukocytes from schizophrenia patients and healthy volunteers. Results Data from 62 studies involving a total sample size of 2298 schizophrenia patients and 1858 healthy volunteers remained for analysis. Ten cytokines were assessed, including the prototypic Th1 and Th2 cytokines gamma interferon (IFN-gamma) and interleukin 4 (IL-4) as well as IL-2, soluble IL-2 receptor (sIL-2R), IL-1beta, IL-1 receptor antagonist (IL-1RA), tumor necrosis factor-alpha (TNF-alpha), IL-6, soluble IL-6 receptor (sIL-6R), and IL-10. The results show that an increase occurs in in vivo IL-1RA, sIL-2R, and IL-6 and a decrease occurs in in vitro IL-2 in schizophrenia. No significant effect sizes were obtained for the other cytokines. Conclusions These findings provide the first evidence of establishment of an inflammatory sy…

Overview

Integrity signals

Registry

Crossref · 10.1016/j.biopsych.2007.09.024

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 10 references

Research works printed but not linked: 88

  1. Brown, 2002, In utero infection and adult schizophrenia, Ment Retard Dev Disabil Res Rev, 8, 51, 10.1002/mrdd.10004 · DOI
  2. Eaton, 2006, Association of schizophrenia and autoimmune diseases: Linkage of Danish national registers, Am J Psychiatry, 163, 521, 10.1176/appi.ajp.163.3.521 · DOI · Paper page
  3. Steinke, 2006, Cytokines and chemokines, J Allergy Clin Immunol, 117, S441, 10.1016/j.jaci.2005.07.001 · DOI
  4. Dinarello, 2005, The many worlds of reducing interleukin-1, Arthritis Rheum, 52, 1960, 10.1002/art.21107 · DOI
  5. Mosmann, 1986, Two types of murine helper T cell clone, J Immunol, 136, 2348, 10.4049/jimmunol.136.7.2348 · DOI
  6. Dong, 2006, Diversification of T-helper-cell lineages: Finding the family root of IL-17-producing cells, Nat Rev Immunol, 6, 329, 10.1038/nri1807 · DOI
  7. Harrington, 2006, Expanding the effector CD4 T-cell repertoire: The Th17 lineage, Curr Opin Immunol, 18, 349, 10.1016/j.coi.2006.03.017 · DOI
  8. McKenzie, 2006, Understanding the IL-23-IL-17 immune pathway, Trends Immunol, 27, 17, 10.1016/j.it.2005.10.003 · DOI
  9. Tato, 2006, Helper T cell differentiation enters a new era: Le roi est mort; vive le roi!, J Exp Med, 203, 809, 10.1084/jem.20060522 · DOI
  10. Muller, 2000, The immune system and schizophrenia, Ann N Y Acad Sci, 917, 456, 10.1111/j.1749-6632.2000.tb05410.x · DOI
  11. Muller, 1999, The role of immune function in schizophrenia: An overview, Eur Arch Psychiatry Clin Neurosci, 249, 62, 10.1007/PL00014187 · DOI
  12. Schwarz, 2001, The Th2-hypothesis of schizophrenia: A strategy to identify a subgroup of schizophrenia caused by immune mechanisms, Med Hypotheses, 56, 483, 10.1054/mehy.2000.1203 · DOI
  13. Schwarz, 2001, T-helper-1 and T-helper-2 responses in psychiatric disorders, Brain Behav Immun, 15, 340, 10.1006/brbi.2001.0647 · DOI
  14. Arolt, 2000, Decreased in vitro production of interferon-gamma and interleukin-2 in whole blood of patients with schizophrenia during treatment, Mol Psychiatry, 5, 150, 10.1038/sj.mp.4000650 · DOI
  15. Bessler, 1995, Cytokine production in drug-free and neuroleptic-treated schizophrenic patients, Biol Psychiatry, 38, 297, 10.1016/0006-3223(94)00299-I · DOI
  16. Kaminska, 2001, Investigation of serum cytokine levels and cytokine production in whole blood cultures of paranoid schizophrenic patients, Arch Immunol Ther Exp (Warsz), 49, 439
  17. Ebrinc, 2002, Serum interleukin 1 alpha and interleukin 2 levels in patients with schizophrenia, J Int Med Res, 30, 314, 10.1177/147323000203000313 · DOI
  18. Maes, 2000, Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics, Eur Neuropsychopharmacol, 10, 119, 10.1016/S0924-977X(99)00062-0 · DOI · Paper page
  19. Akiyama, 1999, Serum levels of soluble IL-2 receptor alpha, IL-6 and IL-1 receptor antagonist in schizophrenia before and during neuroleptic administration, Schizophr Res, 37, 97, 10.1016/S0920-9964(98)00140-6 · DOI
  20. Shintani, 1991, Serum interleukin-6 in schizophrenic patients, Life Sci, 49, 661, 10.1016/0024-3205(91)90112-O · DOI
  21. Gladkevich, 2004, Lymphocytes as a neural probe: Potential for studying psychiatric disorders, Prog Neuropsychopharmacol Biol Psychiatry, 28, 559, 10.1016/j.pnpbp.2004.01.009 · DOI
  22. Ghezzi, 1996, Mechanism of inhibition of tumor necrosis factor production by chlorpromazine and its derivatives in mice, Eur J Pharmacol, 317, 369, 10.1016/S0014-2999(96)00728-5 · DOI
  23. Maes, 1994, Immune-inflammatory markers in schizophrenia: Comparison to normal controls and effects of clozapine, Acta Psychiatr Scand, 89, 346, 10.1111/j.1600-0447.1994.tb01527.x · DOI
  24. Hinze-Selch, 2001, In vitro cytokine secretion in individuals with schizophrenia: results, confounding factors, and implications for further research, Brain Behav Immun, 15, 282, 10.1006/brbi.2001.0645 · DOI
  25. Song, 2001, Methods for exploring heterogeneity in meta-analysis, Eval Health Prof, 24, 126, 10.1177/016327870102400203 · DOI
  26. Avgustin, 2005, Increased Th1 and Th2 immune reactivity with relative Th2 dominance in patients with acute exacerbation of schizophrenia, Croat Med J, 46, 268
  27. Baker, 1996, Serum cytokine concentrations in patients with schizophrenia, Schizophr Res, 20, 199, 10.1016/0920-9964(95)00089-5 · DOI
  28. Barak, 1995, Changes in interleukin-1 beta and soluble interleukin-2 receptor levels in CSF and serum of schizophrenic patients, J Basic Clin Physiol Pharmacol, 6, 61, 10.1515/JBCPP.1995.6.1.61 · DOI
  29. Cazzullo, 1998, Cytokines production in chronic schizophrenia patients with or without paranoid behaviour, Prog Neuropsychopharmacol Biol Psychiatry, 22, 947, 10.1016/S0278-5846(98)00059-1 · DOI
  30. Cazzullo, 2001, Cytokine profiles in drug-naive schizophrenic patients, Schizophr Res, 47, 293, 10.1016/S0920-9964(00)00046-3 · DOI
  31. Cazzullo, 2002, Cytokine profiles in schizophrenic patients treated with risperidone: A 3-month follow-up study, Prog Neuropsychopharmacol Biol Psychiatry, 26, 33, 10.1016/S0278-5846(01)00221-4 · DOI
  32. el-Mallakh, 1993, Interleukin-1 alpha and interleukin-2 in cerebrospinal fluid of schizophrenic subjects, Prog Neuropsychopharmacol Biol Psychiatry, 17, 383, 10.1016/0278-5846(93)90072-Z · DOI
  33. Frommberger, 1997, Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: Comparison between the acute state and after remission, Eur Arch Psychiatry Clin Neurosci, 247, 228, 10.1007/BF02900219 · DOI · Paper page
  34. Ganguli, 1989, Decreased interleukin-2 production in schizophrenic patients, Biol Psychiatry, 26, 427, 10.1016/0006-3223(89)90061-9 · DOI
  35. Ganguli, 1989, Increased serum interleukin 2 receptor concentration in schizophrenic and brain-damaged subjects, Arch Gen Psychiatry, 46, 292, 10.1001/archpsyc.1989.01810030098018 · DOI
  36. Ganguli, 1994, Serum interleukin-6 concentration in schizophrenia: Elevation associated with duration of illness, Psychiatry Res, 51, 1, 10.1016/0165-1781(94)90042-6 · DOI
  37. Ganguli, 1995, Mitogen-stimulated interleukin-2 production in never-medicated, first-episode schizophrenic patients, Arch Gen Psychiatry, 52, 668, 10.1001/archpsyc.1995.03950200058014 · DOI
  38. Gattaz, 1992, Abnormalities in serum concentrations of interleukin-2, interferon-alpha and interferon-gamma in schizophrenia not detected, Schizophr Res, 6, 237, 10.1016/0920-9964(92)90006-Q · DOI
  39. Haack, 1999, Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: Effects of confounding factors and diagnosis, J Psychiatr Res, 33, 407, 10.1016/S0022-3956(99)00021-7 · DOI
  40. Katila, 1994, Plasma and cerebrospinal fluid interleukin-1 beta and interleukin-6 in hospitalized schizophrenic patients, Neuropsychobiology, 30, 20, 10.1159/000119130 · DOI
  41. Kim, 1998, Decreased interleukin-2 production in Korean schizophrenic patients, Biol Psychiatry, 43, 701, 10.1016/S0006-3223(97)00357-0 · DOI
  42. Kim, 2000, Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics, Schizophr Res, 44, 165, 10.1016/S0920-9964(99)00171-1 · DOI
  43. Kim, 2004, Th1, Th2 and Th3 cytokine alteration in schizophrenia, Prog Neuropsychopharmacol Biol Psychiatry, 28, 1129, 10.1016/j.pnpbp.2004.05.047 · DOI
  44. Kowalski, 2001, Neuroleptics normalize increased release of interleukin- 1 beta and tumor necrosis factor-alpha from monocytes in schizophrenia, Schizophr Res, 50, 169, 10.1016/S0920-9964(00)00156-0 · DOI
  45. Kowalski, 2000, In-vitro immunomodulatory effects of haloperidol and perazine in schizophrenia, World J Biol Psychiatry, 1, 190, 10.3109/15622970009150591 · DOI
  46. Lin, 1998, The inflammatory response system in treatment-resistant schizophrenia: Increased serum interleukin-6, Schizophr Res, 32, 9, 10.1016/S0920-9964(98)00034-6 · DOI
  47. Maes, 1995, Plasma-soluble interleukin-2 and transferrin receptor in schizophrenia and major depression, Eur Arch Psychiatry Clin Neurosci, 244, 325, 10.1007/BF02190412 · DOI
  48. Maes, 1995, Interleukin-2 and interleukin-6 in schizophrenia and mania: Effects of neuroleptics and mood stabilizers, J Psychiatr Res, 29, 141, 10.1016/0022-3956(94)00049-W · DOI
  49. Maes, 1997, In vivo immunomodulatory effects of clozapine in schizophrenia, Schizophr Res, 26, 221, 10.1016/S0920-9964(97)00057-1 · DOI
  50. Maes, 2002, Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor, Schizophr Res, 54, 281, 10.1016/S0920-9964(00)00094-3 · DOI
  51. Maes, 1996, Lower plasma CC16, a natural anti-inflammatory protein, and increased plasma interleukin-1 receptor antagonist in schizophrenia: Effects of antipsychotic drugs, Schizophr Res, 21, 39, 10.1016/0920-9964(96)00029-1 · DOI
  52. Mahendran, 2004, Interleukin-2 levels in chronic schizophrenia patients, Ann Acad Med Singapore, 33, 320, 10.47102/annals-acadmedsg.V33N3p320 · DOI
  53. Monteleone, 1997, Plasma levels of interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia: Effects of clozapine treatment, Psychiatry Res, 71, 11, 10.1016/S0165-1781(97)00036-X · DOI
  54. Mullr, 1997, Soluble IL-6 receptors in the serum and cerebrospinal fluid of paranoid schizophrenic patients, Eur Psychiatry, 12, 294, 10.1016/S0924-9338(97)84789-X · DOI
  55. Muller, 1997, Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia, Eur Arch Psychiatry Clin Neurosci, 247, 308, 10.1007/BF02922260 · DOI
  56. Naudin, 1996, Elevated circulating levels of IL-6 in schizophrenia, Schizophr Res, 20, 269, 10.1016/0920-9964(96)00014-X · DOI
  57. Naudin, 1997, A differential role for interleukin-6 and tumor necrosis factor-alpha in schizophrenia?, Schizophr Res, 26, 27, 10.1016/S0920-9964(97)00059-5 · DOI
  58. Nimgaonkar, 1995, Association study of schizophrenia and the IL-2 receptor beta chain gene, Am J Med Genet, 60, 448, 10.1002/ajmg.1320600517 · DOI
  59. O’Donnell, 1996, Increased production of interleukin-2 (IL-2) but not soluble interleukin-2 receptors (sIL-2R) in unmedicated patients with schizophrenia and schizophreniform disorder, Psychiatry Res, 65, 171, 10.1016/S0165-1781(96)02824-7 · DOI
  60. Rapaport, 1989, Elevated levels of soluble interleukin 2 receptors in schizophrenia, Arch Gen Psychiatry, 46, 291, 10.1001/archpsyc.1989.01810030097017 · DOI
  61. Rapaport, 1994, Serum-soluble interleukin-2 receptors in neuroleptic-naive schizophrenic subjects and in medicated schizophrenic subjects with and without tardive dyskinesia, Acta Psychiatr Scand, 90, 311, 10.1111/j.1600-0447.1994.tb01599.x · DOI
  62. Rapaport, 1994, Increased serum soluble interleukin-2 receptors in Caucasian and Korean schizophrenic patients, Biol Psychiatry, 35, 767, 10.1016/0006-3223(94)91137-1 · DOI
  63. Rothermundt, 2000, Cytokine production in unmedicated and treated schizophrenic patients, Neuroreport, 11, 3385, 10.1097/00001756-200010200-00024 · DOI
  64. Rothermundt, 1998, Immunological dysfunction in schizophrenia: A systematic approach, Neuropsychobiology, 37, 186, 10.1159/000026501 · DOI
  65. Rothermundt, 1996, Production of cytokines in acute schizophrenic psychosis, Biol Psychiatry, 40, 1294, 10.1016/S0006-3223(96)00360-5 · DOI
  66. Schattner, 1996, No evidence for autoimmunity in schizophrenia, J Autoimmun, 9, 661, 10.1006/jaut.1996.0086 · DOI
  67. Schwarz, 1998, Autoantibodies against 60-kDa heat shock protein in schizophrenia, Eur Arch Psychiatry Clin Neurosci, 248, 282, 10.1007/s004060050051 · DOI
  68. Sirota, 2005, Effect of neuroleptic administration on serum levels of soluble IL-2 receptor-alpha and IL-1 receptor antagonist in schizophrenic patients, Psychiatry Res, 134, 151, 10.1016/j.psychres.2004.04.012 · DOI
  69. Theodoropoulou, 2001, Cytokine serum levels, autologous mixed lymphocyte reaction and surface marker analysis in never medicated and chronically medicated schizophrenic patients, Schizophr Res, 47, 13, 10.1016/S0920-9964(00)00007-4 · DOI
  70. van Kammen, 1999, Elevated interleukin-6 in schizophrenia, Psychiatry Res, 87, 129, 10.1016/S0165-1781(99)00053-0 · DOI
  71. Villemain, 1987, Decreased production of interleukin-2 in schizophrenia, Ann N Y Acad Sci, 496, 669, 10.1111/j.1749-6632.1987.tb35828.x · DOI
  72. Villemain, 1989, Aberrant T cell-mediated immunity in untreated schizophrenic patients: Deficient interleukin-2 production, Am J Psychiatry, 146, 609, 10.1176/ajp.146.5.609 · DOI
  73. Wilke, 1996, Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients, Eur Arch Psychiatry Clin Neurosci, 246, 279, 10.1007/BF02190280 · DOI
  74. Xu, 1994, Changes of plasma concentrations of interleukin-1 alpha and interleukin-6 with neuroleptic treatment for schizophrenia, Br J Psychiatry, 164, 251, 10.1192/bjp.164.2.251 · DOI
  75. Yang, 1994, An association between anti-hippocampal antibody concentration and lymphocyte production of IL-2 in patients with schizophrenia, Psychol Med, 24, 449, 10.1017/S0033291700027410 · DOI
  76. Zhang, 2002, Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: Association with psychopathology, Schizophr Res, 57, 247, 10.1016/S0920-9964(01)00296-1 · DOI
  77. Zhang, 2002, Decreased production of interleukin-2 (IL-2), IL-2 secreting cells and CD4+ cells in medication-free patients with schizophrenia, J Psychiatr Res, 36, 331, 10.1016/S0022-3956(02)00023-7 · DOI
  78. Zhang, 2004, Changes in serum interleukin-2, −6, and −8 levels before and during treatment with risperidone and haloperidol: Relationship to outcome in schizophrenia, J Clin Psychiatry, 65, 940, 10.4088/JCP.v65n0710 · DOI
  79. Zhang, 2005, Cortisol and cytokines in chronic and treatment-resistant patients with schizophrenia: Association with psychopathology and response to antipsychotics, Neuropsychopharmacology, 30, 1532, 10.1038/sj.npp.1300756 · DOI
  80. Romagnani, 1995, Biology of human TH1 and TH2 cells, J Clin Immunol, 15, 121, 10.1007/BF01543103 · DOI
  81. Lucey, 1996, Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases, Clin Microbiol Rev, 9, 532, 10.1128/CMR.9.4.532 · DOI
  82. Henderson, 2005, Schizophrenia and comorbid metabolic disorders, J Clin Psychiatry, 66, 11
  83. Wirshing, 2004, Schizophrenia and obesity: Impact of antipsychotic medications, J Clin Psychiatry, 65, 13
  84. Juge-Aubry, 2003, Adipose tissue is a major source of interleukin-1 receptor antagonist: Upregulation in obesity and inflammation, Diabetes, 52, 1104, 10.2337/diabetes.52.5.1104 · DOI
  85. Szuster-Ciesielska, 2004, Neuroleptics modulate cytokine and reactive oxygen species production in blood leukocytes of healthy volunteers, Arch Immunol Ther Exp (Warsz), 52, 59
  86. Pollmacher, 1997, Smoking affects plasma-soluble interleukin-2 receptor levels in patients with schizophrenia, Arch Gen Psychiatry, 54, 89, 10.1001/archpsyc.1997.01830130095017 · DOI
  87. Duan, 2004, No association between the promoter variants of tumor necrosis factor alpha (TNF-alpha) and schizophrenia in Chinese Han population, Neurosci Lett, 366, 139, 10.1016/j.neulet.2004.05.039 · DOI
  88. Shirts, 2006, Association study of IL10, IL1beta, and IL1RN and schizophrenia with tag SNPs from a comprehensive database: Suggestive association with rs16944 at IL1beta, Schizophr Res, 88, 235, 10.1016/j.schres.2006.06.037 · DOI

Cited by

Sorted by citations

See all 858

Metadata

Authors
Potvin, S., Stip, E., Sepehry, A. A., Gendron, A., Bah, R., & Kouassi, E.
Venue
Biological Psychiatry
Publisher
Elsevier BV
Published
2008-04
Volume
63
Issue
8
Pages
801-808
ISSN
0006-3223
DOI
10.1016/j.biopsych.2007.09.024
Cited by
858
References
10
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review